Detection of *Helicobacter pylori* in stool specimens by non-invasive antigen enzyme immunoassay in children: multicentre Italian study

Giuseppina Oderda, Anna Rapa, Barbara Ronchi, P Lerro, Maria Pastore, Annamaria Staiano, G L de'Angelis, P Strisciuglio

Helicobacter pylori infection is mainly acquired in childhood and may predispose to peptic ulcer or gastric cancer later in life.¹ Non-invasive diagnostic tools are particularly useful in children as screening tests and for epidemiological studies, but their accuracy has to be tested against that of invasive tests in symptomatic patients before they are used in any particular population.

Of the non-invasive tests now available, serological testing is not accurate in young patients and the ¹³C urea breath test is expensive. In 1998 an enzyme linked immunoassay (ELISA) (Premier-Platinum-HpSA, Meridian Diagnostics, Cincinnati, OH, USA) was approved by the Food and Drug Administration for both diagnosis in adult symptomatic patients, and monitoring the response to treatment. It is now commercially available, but its correlation with gastric infection has not been assessed in children. We evaluated its diagnostic accuracy against invasive tests in children undergoing endoscopy for clinical evaluation, and we determined the cut off values for the paediatric population.

Patients, methods, and results

Stool samples from 203 consecutive symptomatic children (97 male and 106 female; median age 7 (range 0.5-15) years) undergoing endoscopy in six Italian paediatric units were collected at home by parents, frozen at -20°C, and sent to the coordinating centre (Novara). There they were tested according to the manufacturer's instructions, except that a disposable 10 µl loop was used to improve reproducibility of sampling. Plates were read at 450 nm and 450/655 nm and were evaluated by direct visual reading without use of a plate reader (yellow microwell = positive, white microwell = negative). Stool testing was performed blind, without knowledge of the other test results. The cut off for chil-

dren was determined with a receiver operating characteristic curve, confidence intervals were calculated by the exact method and likelihood ratios by CATmaker program (<http://cebmr2.ox.ac.uk/docs/nomogram.html>), and values were expressed as optical densities.

At endoscopy, biopsy specimens from the antrum and gastric body were taken for histology, microscopic identification of *H pylori* (Giemsa staining), and urease testing. Patients were regarded as *H pylori* positive if *H pylori* was seen at histology and results of the urease test were positive, and as *H pylori* negative when both tests gave negative results. When histology and the urease test gave conflicting results the results of the urea breath test or culture were used if available (urea breath test and culture were routinely performed in only two centres).

Altogether 146 children were *H pylori* negative and 52 *H pylori* positive (49 children had positive results of both the urease test and histology; in two, histology was negative but results of the urea breath test and culture were positive; and in one, the result of the urease test was negative but histology and the result of the urea breath test were positive); and five cases were considered indeterminate because histology and the result of the urease test conflicted and no other test was available.

The sensitivity of the immunoassay was high, but the specificity and accuracy decreased to 93% and 95% respectively when the cut off suggested by the manufacturer for adults²⁻³ was used and because a grey zone was used. With direct visual reading, sensitivity slightly decreased but specificity and accuracy significantly increased ($P = 0.01$; table). When we used the cut off calculated from a receiver operating characteristic curve (0.185 at 450 nm and 0.135 at 450/655 nm) false positive results were obtained in only two cases and the sensitivity was 98%, specificity 99%, accuracy 98%, likelihood ratio positive 72, and likelihood ratio negative 0.02.

Paediatric Endoscopy Units, Università del Piemonte Orientale, 28100 Novara, Italy
Giuseppina Oderda
researcher

Barbara Ronchi
research fellow

Paediatric Research Laboratory, Università del Piemonte Orientale
Anna Rapa
head

Paediatric Endoscopy Units, Turin University, Piazza Polonia 94, 10126 Turin
P Lerro
medical assistant

Paediatric Endoscopy Units, Viale Cappuccini, 71013 San Giovanni Rotondo
Maria Pastore
medical assistant

Paediatric Endoscopy Units, Naples University, Via Pansani 5, 80131 Naples
Annamaria Staiano
researcher

continued over

BMJ 2000;320:347-8

Test performance calculated according to different reading techniques (at 450 nm or double reading at 450/655 nm or by direct visual reading without use of plate reader) and to different cut off values as suggested by manufacturer

Reading technique	Cut off according to manufacturer	Result				Sensitivity (%) (95% CI)	Specificity (%) (95% CI)	Accuracy (%) (95% CI)	Likelihood ratio (95% CI)		No of cases in grey zone*
		True positive	False negative	True negative	False positive				Positive	Negative	
Reading at 450 nm	Negative <0.140, grey zone 0.140-0.160, positive >0.160	52	0	136	10	100 (93.2 to 100)	93 (87.8 to 96.7)	95 (90.9 to 97.6)	15 (7.6 to 30.3)	0 (0 to 0.08)	<i>H pylori</i> positive=0† <i>H pylori</i> negative=4
Reading at 450/655 nm	Negative <0.100, grey zone 0.100-0.120, positive >0.120	52	0	136	10	100 (93.2 to 100)	93 (87.8 to 96.7)	95 (90.9 to 97.6)	15 (7.6 to 30.3)	0 (0 to 0.08)	<i>H pylori</i> positive=0† <i>H pylori</i> negative=4
Direct visual reading	NA	49	3	144	2	94 (84.1 to 98.8)	99 (95.1 to 99.8)	97 (94.2 to 99.2)	69 (17.2 to 494)	0.06 (0.01 to 0.17)	NA

NA=Not applicable.

*According to manufacturer, these cases should be considered equivocal and second stool sample should be tested. The four *H pylori* negative results are included in the 10 false positives.

†According to invasive tests (histology plus urease test or culture).

Paediatric
Endoscopy Units,
Parma University,
Via A Gramsci 14,
43100 Parma
G L de'Angelis
researcher

Paediatric
Endoscopy Units,
Via T Campanella,
88100 Catanzaro
P Strisciuglio
director of paediatric
department

Correspondence to:
G Oderda oderda@
med.unipmn.it

Comment

The enzyme linked immunoassay that we assessed is highly accurate in diagnosing childhood *H pylori* infection. The use of a grey zone may lower its accuracy, but the accuracy is satisfactory even with direct visual reading of the microwells without use of a plate reader; this makes it fairly cheap as a screening test (one determination cost is 22 euro (£14), half the average price of the urea breath test) and practical for epidemiological studies.

This study was approved by and conducted within the guidelines of the gastric disease section of the Italian Society for Paediatric Gastroenterology and Hepatology.

Contributors: GO designed and coordinated the study and wrote the article. AR and BR collected the data from each centre, analysed the faecal samples and did the statistical analysis. PL, MP, AS, GLde'A, and PS all participated in the discussion about the design of the study and approved the study proposal

and the final draft; they also recruited all cases and collected data from patients from each centre, did endoscopy in children, and collected faecal samples to be sent to the coordinator centre. GO will act as guarantor for the paper.

Funding: Meridian Diagnostic Europe partially sponsored the study and provided free kits.

Competing interests: GO and AR have been reimbursed by Meridian Diagnostics, Europe (the manufacturer of HpSA) for attending a symposium on *H pylori* and gastroduodenal disease in Helsinki.

- 1 Blaser MJ, Chyou PH, Nomura A. Age at establishment of *Helicobacter pylori* infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. *Cancer Res* 1995;55:562-5.
- 2 Makristathis A, Pasching E, Schutze K, Wimmer M, Rotter ML, Hirschl AM. Detection of *Helicobacter pylori* in stool specimens by PCR and antigen enzyme immunoassay. *J Clin Microbiol* 1998;36:2772-4.
- 3 Vaira D, Malfertheiner P, Megraud F, Axon ATR, Deltenre M, Hirschl AM, et al, and European *Helicobacter pylori* HpSA Study Group. Diagnosis of *Helicobacter pylori* infection using a novel, non-invasive antigen based assay in a European multicentre study. *Lancet* 1999;354:30-3.

(Accepted 7 October 1999)

Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study

Sheila Stallard, Janet C Litherland, Carolyn M Cordiner, Hilary M Dobson, W David George, Elizabeth A Mallon, David Hole

University
Departments of
Surgery and
Pathology, North
Glasgow Hospitals
University NHS
Trust, Glasgow
G11 6NT

Sheila Stallard
staff grade surgeon
Janet C Litherland
consultant radiologist
Carolyn M Cordiner
consultant radiologist
Hilary M Dobson
consultant radiologist
W David George
professor of surgery
Elizabeth A Mallon
consultant pathologist

West of Scotland
Cancer Surveillance
Unit, University
Department of
Public Health,
Glasgow G12 8RZ
David Hole
principal
epidemiologist

Correspondence to:
S Stallard
dr37d@udcs.
gla.ac.uk

BMJ 2000;320:348-9

Hormone replacement therapy is being used increasingly. Although it is known that the risk of developing breast cancer is slightly increased with long term use,¹ hormone replacement does not seem to adversely affect mortality from breast cancer.²

Studies have suggested that users of hormone replacement who get breast cancer develop tumours with "favourable" pathological features compared with non-users. One study included women who had been detected at screening and women who had presented with symptoms, with more screen detected women in the study group (users) than in the controls (non-users).² Another study compared type of tumour in users and non-users in a screen detected population alone³ and showed that grade 1, node negative tumours were more common in the users.

Women with breast cancer who have used hormone replacement, however, may be more likely to have a cancer that was missed at screening; we have shown that women who develop such cancers (interval cancers) within a year of screening are twice as likely to have been using hormone replacement when they were screened.⁴ We compared pathological features of tumours in both screen detected and interval cancers to assess whether previous use of hormone replacement therapy improves prognosis among women who develop breast cancer.

Patients, methods, and results

The study population comprised all 1130 women aged 50-64 years who underwent routine breast screening during May 1988 to December 1993 in the area of Scotland covered by the West of Scotland Breast Screening Unit and who either had a screen

detected cancer or developed an interval cancer. Data on interval cancers were collected up to the end of 1996. Current use of hormone replacement (yes/no) had been recorded by radiographers at the time of screening and also at assessment for women with screen detected cancers. The case notes of half the women with interval cancers were reviewed to check whether use of hormone replacement at the time of presentation was the same as at their last screening. Seventeen women were excluded because use of hormone replacement was unknown, leaving 1113 patients for analysis.

Of the 815 women with screen detected cancers, 100 (12.3%) were using hormone replacement when they were screened. Of the 298 women with interval cancer, 66 (22.1%) were using hormone replacement; use at diagnosis was the same as at their previous screen. Of the total number of women studied, therefore, 166 (14.9%) were using hormone replacement at the time they developed breast cancer.

We found no difference in type, size, or grade of tumour in users compared with non-users (table). Twenty four per cent of users developed well differentiated tumours (tubular, mucoid, and invasive ductal grade 1 cancers) compared with 22% of non-users. This equates to an odds ratio of 0.98 (95% confidence interval 0.63 to 1.50). Seventy seven per cent of users were node negative compared with 67% of non-users. There was no difference in mean tumour size (mean difference 0.25 mm (-2.02 mm to 2.53 mm)) in users compared with non-users. No difference was seen in the distribution of the Nottingham prognostic index⁵ between the two groups. Eight per cent of women using hormone replacement developed ductal carcinoma in situ compared with 15% of non-users. When